5 Surprising Signs of Aging
Jancee Dunn / nytimes - Hint: You may need to buy new shoes.
AI Summary: Phase III DESTINY‑Lung04 data show trastuzumab deruxtecan (Enhertu) significantly prolongs progression‑free survival as first‑line therapy for HER2‑mutant non‑small cell lung cancer. Investigators hail the efficacy signal, but oncologists caution that longer follow‑up is needed to determine whether the PFS benefit will translate into overall survival advantage.
Related Stories
Engineered bacteria show promise as tumor‑targeting therapy in preclinical studies / 5 wks
Daraxonrasib shows encouraging activity in NRAS-driven melanoma patients / 6 wks
Rogaratinib shows activity in SDH‑deficient GIST phase 2 trial / 3 months
Genetic clues explain tagraxofusp resistance in rare leukemia (BPDCN) / 7 wks
Adjuvant selpercatinib sharply cuts recurrence in RET‑fusion lung cancer / 2 months
CRISPR CD33‑deleted allogeneic transplant shows early AML promise / 3 months
Single‑cycle pembrolizumab yields striking responses in dMMR colon cancer / 3 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Obesity, Biotech, Public Health, Genetics and look for the RSS link.
StackHealth Time Machine